Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Lucas

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Leukemia|August 28, 2009
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transportersA Davies, N E Jordanides, A Giannoudis, et al.
International Immunology|January 1, 1990
Blood leukocytes bind platelet glycoprotein (IIb-IIIa)' but do not express the vitronectin receptorG W Krissansen, C M Lucas, F C Stomski, et al.
Leukemia|August 30, 2008
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trialsC M Lucas, L Wang, G M Austin, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Leukemia|August 28, 2009
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transportersA Davies, N E Jordanides, A Giannoudis, et al.
International Immunology|January 1, 1990
Blood leukocytes bind platelet glycoprotein (IIb-IIIa)' but do not express the vitronectin receptorG W Krissansen, C M Lucas, F C Stomski, et al.
Leukemia|August 30, 2008
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trialsC M Lucas, L Wang, G M Austin, et al.
Pageof 5